View Item 

Show simple item record

Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
dc.contributor.authorHoffman, Stephanie
dc.contributor.authorBraunreiter, Chi
dc.date.accessioned2017-10-23T17:31:14Z
dc.date.available2018-12-03T15:34:05Zen
dc.date.issued2017-10
dc.identifier.citationHoffman, Stephanie; Braunreiter, Chi (2017). "Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review." Research and Practice in Thrombosis and Haemostasis 1(2): 188-193.
dc.identifier.issn2475-0379
dc.identifier.issn2475-0379
dc.identifier.urihttps://hdl.handle.net/2027.42/138884
dc.description.abstractEssentialsData is scarce on enoxaparin dosing for obese adolescents with venous thromboembolism (VTE).Overweight and obese adolescents treated with reduced enoxaparin dose (RD) were reviewed.Initial enoxaparin doses calculated using actual body weight may be greater than what is needed.Trials are warranted to evaluate RD enoxaparin for overweight and obese adolescents with VTE.BackgroundThe global obesity epidemic has created new challenges, including venous thromboembolisms (VTE) in obese adolescents. The data on whether to reduce the dose of low‐molecular heparin in obese adults is conflicting, and information on adolescent patients is scarce.ObjectivesOur primary goal was to describe dosing, anti‐Xa levels, and outcomes of overweight and obese adolescents who received reduced doses of enoxaparin at the initiation of therapy. The secondary goal was to compare their outcomes to overweight and obese adolescents who received standard 1 mg/kg dosing to determine if future trials for dose reduction are warranted.Patients/MethodsWe performed a retrospective cohort study of overweight and obese patients between the ages of 12 and 18 years old diagnosed with VTE who were treated with reduced dosing (RD) of enoxaparin, comparing their dosing, anti‐Xa levels, and outcomes to overweight and obese adolescents who received standard dosing (SD).ResultsRD patients (n=19) achieved therapeutic mean initial anti‐Xa levels that were similar to SD patients (n=11). Of the RD patients, 53% did not require dose adjustments during treatment. Two RD patients had thrombus progression. A total of 25 patients ultimately completed therapy with RD.ConclusionsFuture trials are warranted to evaluate the efficacy and safety of reduced dosing of enoxaparin to treat overweight and obese adolescents with VTE.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherobesity
dc.subject.otherthromboembolism
dc.subject.otherthrombosis
dc.subject.otherenoxaparin
dc.subject.otheradolescent
dc.titleReduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138884/1/rth212032_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138884/2/rth212032.pdf
dc.identifier.doi10.1002/rth2.12032
dc.identifier.sourceResearch and Practice in Thrombosis and Haemostasis
dc.identifier.citedreferenceBernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child. 1986; 140: 667 – 71.
dc.identifier.citedreferenceThompson‐Moore NR, Wanat MA, Putney DR, Liebl PH, Chandler WL, Muntz JE. Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity. Clin Appl Thromb Hemost. 2015; 21: 513 – 20.
dc.identifier.citedreferenceLalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2015; 39: 516 – 21.
dc.identifier.citedreferenceHirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low‐molecular‐weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119: 64S – 94S.
dc.identifier.citedreferenceLaposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference I on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low‐molecular‐weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998; 122: 799 – 807.
dc.identifier.citedreferenceHarenberg J. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes. J Thromb Haemost. 2004; 2: 547 – 50.
dc.identifier.citedreferenceBounameaux H, de Moerloose P. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? No. J Thromb Haemost. 2004; 2: 551 – 4.
dc.identifier.citedreferenceSpentzouris G, Scriven RJ, Lee TK, Labropoulos N. Pediatric venous thromboembolism in relation to adults. J Vasc Surg. 2012; 55: 1785 – 93.
dc.identifier.citedreferenceBarras MA, Kirkpatrick CM, Green B. Current dosing of low‐molecular‐weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol. 2010; 69: 520 – 8.
dc.identifier.citedreferenceLewis TV, Johnson PN, Nebbia AM, Dunlap M. Increased enoxaparin dosing is required for obese children. Pediatrics. 2011; 127: e787 – 90.
dc.identifier.citedreferenceMushtaq A, Vaughns JD, Ziesenitz VC, Nadler EP, van den Anker JN. Use of enoxaparin in obese adolescents during bariatric surgery–a pilot study. Obes Surg. 2015; 25: 1869 – 74.
dc.identifier.citedreferenceBarlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 ( Suppl 4 ): S164 – 92.
dc.identifier.citedreferenceSchwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4: 1832 – 43.
dc.identifier.citedreferenceGoldenberg NA, Abshire T, Blatchford PJ, et al. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. J Thromb Haemost. 2015; 13: 1597 – 605.
dc.identifier.citedreferenceRichard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D Jr, Yee DL. Comparison of anti‐Xa levels in obese and non‐obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013; 162: 293 – 6.
dc.identifier.citedreferenceNowak‐Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008; 153: 1120 – 7.
dc.identifier.citedreferenceMismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta‐analysis. Chest. 2005; 128: 2203 – 10.
dc.identifier.citedreferenceSiragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low‐molecular‐weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta‐analysis. Am J Med. 1996; 100: 269 – 77.
dc.identifier.citedreferencePrentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006; 35: 93 – 9.
dc.identifier.citedreferenceOgden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988‐1994 through 2013‐2014. JAMA. 2016; 315: 2292 – 9.
dc.identifier.citedreferenceYang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012; 2: 499 – 509.
dc.identifier.citedreferenceEichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008; 168: 1678 – 83.
dc.identifier.citedreferenceBorch KH, Braekkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso study. J Thromb Haemost. 2009; 7: 739 – 45.
dc.identifier.citedreferenceVu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg. 2008; 43: 1095 – 9.
dc.identifier.citedreferenceHalvorson EE, Ervin SE, Russell TB, Skelton JA, Davis S, Spangler J. Association of obesity and pediatric venous thromboembolism. Hosp Pediatr. 2016; 6: 22 – 6.
dc.identifier.citedreferenceMerkel N, Gunther G, Schobess R. Long‐term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol. 2006; 115: 230 – 6.
dc.identifier.citedreferenceMonagle P, Chan AK, Goldenberg NA, et al. Physicians ACoC. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012; 141: e737S – 801S.
dc.identifier.citedreferenceSanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002; 72: 308 – 18.
dc.identifier.citedreferenceBazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005; 116: 41 – 50.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
rth212032_am.pdf
Size:
171.5KB
Format:
PDF
View/Open
Name:
rth212032.pdf
Size:
477.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.